Theracos Bio

Theracos Bio is a pharmaceutical company focused on providing cost-effective treatments for complex diseases, with a primary emphasis on metabolic disorders. The company's lead product, Brenzavvy (bexagliflozin), is an oral SGLT2 inhibitor approved by the FDA for the treatment of type 2 diabetes in adults. Theracos Bio distinguishes itself through a mission-driven approach to drug pricing, aiming to increase patient access to essential medications. The company operates as a private entity and collaborates with partners like Mark Cuban Cost Plus Drug Company to distribute its therapies. By leveraging a lean corporate structure, the company focuses on delivering high-quality clinical data and affordable therapeutic options.